GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (CHIX:XBRANs) » Definitions » Profitability Rank

Xbrane Biopharma AB (CHIX:XBRANS) Profitability Rank : 3 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Xbrane Biopharma AB Profitability Rank?

Xbrane Biopharma AB has the Profitability Rank of 3. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Xbrane Biopharma AB's Operating Margin % for the quarter that ended in Mar. 2024 was -603.82%. As of today, Xbrane Biopharma AB's Piotroski F-Score is 2.


Competitive Comparison of Xbrane Biopharma AB's Profitability Rank

For the Biotechnology subindustry, Xbrane Biopharma AB's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xbrane Biopharma AB's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Profitability Rank falls into.



Xbrane Biopharma AB Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Xbrane Biopharma AB has the Profitability Rank of 3. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Xbrane Biopharma AB's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-85.138 / 14.1
=-603.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Xbrane Biopharma AB has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Good Sign:

Xbrane Biopharma AB operating margin is expanding. Margin expansion is usually a good sign.

4. Consistency of the profitability

5. Predictability Rank


Xbrane Biopharma AB Profitability Rank Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Xbrane Biopharma AB (CHIX:XBRANS) Business Description

Traded in Other Exchanges
Address
Retzius vag 8, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (CHIX:XBRANS) Headlines

No Headlines